Nanochon Abstract Presented at AAOS 2026
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes 4, Brad B Nelson 1,
2025 Fourth Quarter Update
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This round was led by Ecphora
UVAToday Features Nanochon
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint the exact moment he fell
Nanochon closes $4.1M Seed Prime II Funding Round
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured
Cadaveric Evaluation of Three Novel Cartilage Repair Implants
Emilia Aram , David C. Flanigan, MD, Nathan J. Castro, PhD, Doug Snell, Luke Aram Purpose: Osteochondral defects can present a significant source of pain
Treatment of full thickness cartilage lesions with a 3D Printed Nanochon Implant in an Equine model
Charlotte K Barton BVSc, MS, DACVS-LA, MS, MS, Katie A Seabaugh DVM, MS, DACVS-LA, DACVSMR, Ben Gadomski BS, PhD, Kevin Labus PhD, Ben Holmes BS,
2025 Third Quarter Update
Nanochon has secured commitments to close oversubscribed convertible note, bringing our total capital raised to date to $11.3 million. While the majority of this bridge was filled by current investors, we’re thrilled to welcome a few new folks onto our cap table.
The Maryland Stem Cell Research Commission Awards Nanochon Grant Funding
The Maryland Stem Cell Research Commission, the body overseeing The Maryland Stem Cell Research Fund (MSCRF), has awarded Nanochon grant funding to support its manufacturing
Nanochon Announces Health Canada Approval for First in Human Investigation
Washington, DC, July 14 2025 – Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects
Nanochon Creating a New Clinical Standard for Cartilage Restoration
Under the direction of CEO Benjamin Holmes, Nanochon, Inc. is set to revolutionize the treatment of cartilage loss and damage. The company’s Chondrograft™ implant, a